Skip to content

The background image is Female medical practitioner reassuring a patient

Penn State has a portfolio of clinical outcome assessments (COAs) and patient-reported outcome measures (PROs) for the assessment of hidradenitis suppurativa (HS). The PRO portfolio includes condition-specific questionnaires designed to assess quality-of-life (QOL).

  • HiSQOL™: Hidradenitis Suppurativa Quality of Life instrument
  • HiSQOL-Adolescent: Hidradenitis Suppurativa Quality of Life instrument, adapted for Adolescents
  • HS PtGA: HS Patient Global Assessment of Quality of Life
  • HASI-R: Hidradenitis Suppurativa Area and Severity Index, revised

Use the buttons below to explore each instrument or request a copyright license.

HiSQOL

Hidradenitis Suppurativa Quality of Life instrument

  • Background

    The HiSQOL™ is an HS-specific quality-of-life instrument that is of particular importance as it is sensitive to the unique symptoms and experiences of patients with HS.

    The HiSQOL™ is a validated and reliable tool for the assessment of HS-specific quality-of-life.

    HiSQOL, Hidradentitis Suppurativa - Quality of Life

    Instrument

    The HiSQOL™ is a 17-item HS-specific questionnaire used to assess participants’ QOL, with a recall period of seven days. Each item is structured as a Likert-type scale with five or seven response levels and, for all items, the score ranges from 0 (not at all) to 4 (extremely). Some items also have response options for when an item is not performed, either because it’s not relevant or due to HS severity. The HiSQOL items address HS symptoms, psychosocial and emotional impacts, as well as activities and adaptations related to HS.

    The HiSQOL is available in 70 languages.

    Request a License

  • Development

    A mixed methods design was utilized and included four phases aligned with guidance from the U.S. Food and Drug Administration. The development of the HiSQOL™ was overseen by an international group of investigators, which included patient research partners, clinicians with expertise in HS and researchers with expertise in instrument development. The initial psychometric properties of the HiSQOL were studied in a cross-sectional observational study of 215 participants with moderate-to-severe HS. Subsequently, the psychometric properties of the HiSQOL were confirmed and expanded through analysis of HiSQOL data collected from two Phase III pivotal trials.

    The HiSQOL instrument has been validated for use of the total score as well as subscale scores, determined clinically meaningful within-patient change thresholds for the HiSQOL subscale and total scores and established score categories. Details of the development of the HiSQOL can be found in the References.

  • Scoring

    The total score for the HiSQOL is calculated from the sum of the 17 item scores, which has a total score range of 0 to 68. Additionally, the HiSQOL has three validated subscale scores that can be derived from the item scores: symptoms (with a score range of 0 to 16), psychosocial (with a score range of 0 to 20) and activities-adaptations (with a score range of 0 to 32), with a higher score indicating a higher level of symptomology in all subscales.

    The following ranges are recommended to represent a marked clinically meaningful within-patient improvement.

    • Symptoms subscale: 5- to 6-point decrease (i.e., 31% to 38% of the score range)
    • Psychosocial subscale: 4- to 5-point decrease (i.e., 20% to 25% of the score range)
    • Activities-adaptations subscale: 10- to 11-point decrease (i.e., 31% to 34% of the score range)
    • Total score: 20- to 21-point decrease (i.e., 29% to 31% of the score range).

    Additional details of scoring and interpretation of the HiSQOL scores can be found in the References.

  • References

    Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. Aug 2020;183(2):340-348. doi:10.1111/bjd.18692.

    Kursawe Larsen C, Kjaersgaard Andersen R, Kirby JS, Tan J, Saunte DML, Jemec GBE. Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1577-1581. doi: 10.1111/jdv.17148.

    Kirby JS, Ingram JR, Lambert J, Rolleri R, Muller E, Pansar I, Pelligra C. Determination of Bands of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Threshold and Severity Levels. ISPOR-EU 2023; November 12-15, 2023; Copenhagen, Denmark.

  • Languages

    Afrikaans for South Africa

    Arabic for Israel

    Bulgarian for Bulgaria

    Catalan for Spain

    Cebuano for the Philippines

    Chinese simplified for China

    Chinese simplified for Malaysia

    Chinese simplified for Singapore

    Chinese traditional for Taiwan

    Croatian for Croatia

    Czech for the Czech Republic

    Danish for Denmark

    Dutch for Belgium

    Dutch for the Netherlands

    English for Australia

    English for Canada

    English for Ireland

    English for Israel

    English for Malaysia

    English for New Zealand

    English for Phillipines

    English for Singapore

    English for South Africa

    English for the United Kingdom

    English for the United States (original)

    Finnish for Finland

    French for Belgium

    French for Canada

    French for France

    French for Switzerland

    Galacian for Spain

    German for Austria

    German for Belgium

    German for Germany

    German for Switzerland

    Greek for Greece

    Hebrew for Israel

    Hilgaynon for Philippines

    Hungarian for Hungary

    Italian for Italy

    Italian for Switzerland

    Japanese for Japan

    Korean for South Korea

    Lithuanian for Lithuania

    Malay for Malaysia

    Malay for Singapore

    Mandarin for China

    Norwegian for Norway

    Polish for Poland

    Portuguese for Portugal

    Russian for Israel

    Russian for Lithuania

    Russian for Russia

    Slovak for Slovakia

    Spanish for Argentina

    Spanish for Chile

    Spanish for Colombia

    Spanish for Guatemala

    Spanish for Mexico

    Spanish for Puerto Rico

    Spanish for Spain

    Spanish for the United States

    Swedish for Sweden

    Tagalog for Phillipines

    Tamil for Malaysia

    Tamil for Singapore

    Turkish for Turkey

    Vietnamese for Vietnam

    Xhosa for South Africa

    Zulu for South Africa

Background

The HiSQOL™ is an HS-specific quality-of-life instrument that is of particular importance as it is sensitive to the unique symptoms and experiences of patients with HS.

The HiSQOL™ is a validated and reliable tool for the assessment of HS-specific quality-of-life.

HiSQOL, Hidradentitis Suppurativa - Quality of Life

Instrument

The HiSQOL™ is a 17-item HS-specific questionnaire used to assess participants’ QOL, with a recall period of seven days. Each item is structured as a Likert-type scale with five or seven response levels and, for all items, the score ranges from 0 (not at all) to 4 (extremely). Some items also have response options for when an item is not performed, either because it’s not relevant or due to HS severity. The HiSQOL items address HS symptoms, psychosocial and emotional impacts, as well as activities and adaptations related to HS.

The HiSQOL is available in 70 languages.

Request a License

Development

A mixed methods design was utilized and included four phases aligned with guidance from the U.S. Food and Drug Administration. The development of the HiSQOL™ was overseen by an international group of investigators, which included patient research partners, clinicians with expertise in HS and researchers with expertise in instrument development. The initial psychometric properties of the HiSQOL were studied in a cross-sectional observational study of 215 participants with moderate-to-severe HS. Subsequently, the psychometric properties of the HiSQOL were confirmed and expanded through analysis of HiSQOL data collected from two Phase III pivotal trials.

The HiSQOL instrument has been validated for use of the total score as well as subscale scores, determined clinically meaningful within-patient change thresholds for the HiSQOL subscale and total scores and established score categories. Details of the development of the HiSQOL can be found in the References.

Scoring

The total score for the HiSQOL is calculated from the sum of the 17 item scores, which has a total score range of 0 to 68. Additionally, the HiSQOL has three validated subscale scores that can be derived from the item scores: symptoms (with a score range of 0 to 16), psychosocial (with a score range of 0 to 20) and activities-adaptations (with a score range of 0 to 32), with a higher score indicating a higher level of symptomology in all subscales.

The following ranges are recommended to represent a marked clinically meaningful within-patient improvement.

  • Symptoms subscale: 5- to 6-point decrease (i.e., 31% to 38% of the score range)
  • Psychosocial subscale: 4- to 5-point decrease (i.e., 20% to 25% of the score range)
  • Activities-adaptations subscale: 10- to 11-point decrease (i.e., 31% to 34% of the score range)
  • Total score: 20- to 21-point decrease (i.e., 29% to 31% of the score range).

Additional details of scoring and interpretation of the HiSQOL scores can be found in the References.

References

Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. Aug 2020;183(2):340-348. doi:10.1111/bjd.18692.

Kursawe Larsen C, Kjaersgaard Andersen R, Kirby JS, Tan J, Saunte DML, Jemec GBE. Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1577-1581. doi: 10.1111/jdv.17148.

Kirby JS, Ingram JR, Lambert J, Rolleri R, Muller E, Pansar I, Pelligra C. Determination of Bands of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Threshold and Severity Levels. ISPOR-EU 2023; November 12-15, 2023; Copenhagen, Denmark.

Languages

Afrikaans for South Africa

Arabic for Israel

Bulgarian for Bulgaria

Catalan for Spain

Cebuano for the Philippines

Chinese simplified for China

Chinese simplified for Malaysia

Chinese simplified for Singapore

Chinese traditional for Taiwan

Croatian for Croatia

Czech for the Czech Republic

Danish for Denmark

Dutch for Belgium

Dutch for the Netherlands

English for Australia

English for Canada

English for Ireland

English for Israel

English for Malaysia

English for New Zealand

English for Phillipines

English for Singapore

English for South Africa

English for the United Kingdom

English for the United States (original)

Finnish for Finland

French for Belgium

French for Canada

French for France

French for Switzerland

Galacian for Spain

German for Austria

German for Belgium

German for Germany

German for Switzerland

Greek for Greece

Hebrew for Israel

Hilgaynon for Philippines

Hungarian for Hungary

Italian for Italy

Italian for Switzerland

Japanese for Japan

Korean for South Korea

Lithuanian for Lithuania

Malay for Malaysia

Malay for Singapore

Mandarin for China

Norwegian for Norway

Polish for Poland

Portuguese for Portugal

Russian for Israel

Russian for Lithuania

Russian for Russia

Slovak for Slovakia

Spanish for Argentina

Spanish for Chile

Spanish for Colombia

Spanish for Guatemala

Spanish for Mexico

Spanish for Puerto Rico

Spanish for Spain

Spanish for the United States

Swedish for Sweden

Tagalog for Phillipines

Tamil for Malaysia

Tamil for Singapore

Turkish for Turkey

Vietnamese for Vietnam

Xhosa for South Africa

Zulu for South Africa

HiSQOL-Adolescent

Hidradenitis Suppurativa Quality of Life instrument, adapted for Adolescents

  • Background

    Hidradenitis suppurativa (HS) can have a large negative impact on health-related quality of life (HRQOL). Thus, HS-Specific HRQOL assessment is recommended for measurement in clinical trials. The Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale was developed to validly and reliably measure HS-specific HRQOL for adults (18 years of age and older) with HS. Thus, there was a need for a scale for use with adolescents with HS. The objective of our work study has been to investigate the validity and reliability of the adaptation of the HiSQOL for adolescents with moderate-to-severe HS.

    Instrument

    The HiSQOL-Adolescent is an HS-specific quality of life instrument that has been adapted for use in adolescents, specifically patients 12 years of age to less than 18 years of age. The HiSQOL-Adolescent is also sensitive to the unique symptoms and experiences of patients with HS. The HiSQOL-Adolescent demonstrates face validity and convergent validity. Its responsiveness to change and score interpretation have not been established.

    The HiSQOL is available in 70 languages; however, the HiSQOL-Adolescent adaptations have not been incorporated into languages other than English.

    Request a License

  • Development

    A qualitative study was conducted and following relevant ethics board approval. Interviews were conducted with HS patients aged 11 to <18 years-old at a center in the United States and a second site in Cardiff, United Kingdom. Details of the development of the HiSQOL can be found in the References. The face validity of the HiSQOL was confirmed in the cognitive debriefings as participants indicated the instrument was exciting and assessed relevant symptoms and impacts of the condition. Quantitative analyses on the subset showed positive results. Content validity was supported by a strong Pearson correlation between the HiSQOL and CDLQI (r=0.92; p=0.01). The reliability for HiSQOL, using the Cronbach alpha, was also strong (a=0.98). Based on feedback, two items related to sexual activity and desire were removed and one item related to exercise was re-worded.

  • Scoring

    Score methodology is conserved from the adult version, with modifications for the reduced number of items. The total score for the HiSQOL-Adolescent is calculated from the sum of the 15 item scores, which has a total score range of 0 to 60. The construct validity of the subscores has not been validated, and interpretation of scores will need to be confirmed. As with the HiSQOL, a higher score indicates a higher level of symptomology.

  • References

    Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. Aug 2020;183(2):340-348. doi:10.1111/bjd.18692

Background

Hidradenitis suppurativa (HS) can have a large negative impact on health-related quality of life (HRQOL). Thus, HS-Specific HRQOL assessment is recommended for measurement in clinical trials. The Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale was developed to validly and reliably measure HS-specific HRQOL for adults (18 years of age and older) with HS. Thus, there was a need for a scale for use with adolescents with HS. The objective of our work study has been to investigate the validity and reliability of the adaptation of the HiSQOL for adolescents with moderate-to-severe HS.

Instrument

The HiSQOL-Adolescent is an HS-specific quality of life instrument that has been adapted for use in adolescents, specifically patients 12 years of age to less than 18 years of age. The HiSQOL-Adolescent is also sensitive to the unique symptoms and experiences of patients with HS. The HiSQOL-Adolescent demonstrates face validity and convergent validity. Its responsiveness to change and score interpretation have not been established.

The HiSQOL is available in 70 languages; however, the HiSQOL-Adolescent adaptations have not been incorporated into languages other than English.

Request a License

Development

A qualitative study was conducted and following relevant ethics board approval. Interviews were conducted with HS patients aged 11 to <18 years-old at a center in the United States and a second site in Cardiff, United Kingdom. Details of the development of the HiSQOL can be found in the References. The face validity of the HiSQOL was confirmed in the cognitive debriefings as participants indicated the instrument was exciting and assessed relevant symptoms and impacts of the condition. Quantitative analyses on the subset showed positive results. Content validity was supported by a strong Pearson correlation between the HiSQOL and CDLQI (r=0.92; p=0.01). The reliability for HiSQOL, using the Cronbach alpha, was also strong (a=0.98). Based on feedback, two items related to sexual activity and desire were removed and one item related to exercise was re-worded.

Scoring

Score methodology is conserved from the adult version, with modifications for the reduced number of items. The total score for the HiSQOL-Adolescent is calculated from the sum of the 15 item scores, which has a total score range of 0 to 60. The construct validity of the subscores has not been validated, and interpretation of scores will need to be confirmed. As with the HiSQOL, a higher score indicates a higher level of symptomology.

References

Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. Aug 2020;183(2):340-348. doi:10.1111/bjd.18692

HS PtGA

HS Patient Global Assessment of Quality of Life

  • Background

    Single-item assessments such as a global assessment have been effective in assessing and tracking dermatologic disease severity over time. Simplicity in its use can result in a high compliance rate. Specifically, a patient global assessment (PtGA) can assess a construct comprehensively, such as disease impact on QOL, and allows the patient to consider all contributory factors (such as multiple symptoms, treatments, etc.) related to the condition or disease.

    Instrument

    The HS PtGA is available in English.

    Request a License

  • Development

    Similar to the HiSQOL, a mixed methods design was utilized and included four phases aligned with guidance from the U.S. Food and Drug Administration. The development of the PtGA was overseen by an international group of investigators, which included patient research partners, clinicians with expertise in HS, and researchers with expertise in instrument development. The psychometric properties of the PtGA were studied in a cross-sectional observational study of 215 participants with moderate-to-severe HS. Details of the development of the HS PtGA can be found in the References.

  • Scoring

    A 2-grade reduction has been shown in a cross-sectional study to represent a marked clinically meaningful within-patient improvement. Additional investigation will confirm the score interpretation of the PtGA.

  • References

    Kirby JS, Hereford B, Thorlacius L, Villumsen B, Ingram JR, Garg A, Butt M, Esmann S, King T, Tan J, Jemec GBE. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa. Br J Dermatol. 2021 Apr;184(4):681-687. doi: 10.1111/bjd.19344.

Background

Single-item assessments such as a global assessment have been effective in assessing and tracking dermatologic disease severity over time. Simplicity in its use can result in a high compliance rate. Specifically, a patient global assessment (PtGA) can assess a construct comprehensively, such as disease impact on QOL, and allows the patient to consider all contributory factors (such as multiple symptoms, treatments, etc.) related to the condition or disease.

Instrument

The HS PtGA is available in English.

Request a License

Development

Similar to the HiSQOL, a mixed methods design was utilized and included four phases aligned with guidance from the U.S. Food and Drug Administration. The development of the PtGA was overseen by an international group of investigators, which included patient research partners, clinicians with expertise in HS, and researchers with expertise in instrument development. The psychometric properties of the PtGA were studied in a cross-sectional observational study of 215 participants with moderate-to-severe HS. Details of the development of the HS PtGA can be found in the References.

Scoring

A 2-grade reduction has been shown in a cross-sectional study to represent a marked clinically meaningful within-patient improvement. Additional investigation will confirm the score interpretation of the PtGA.

References

Kirby JS, Hereford B, Thorlacius L, Villumsen B, Ingram JR, Garg A, Butt M, Esmann S, King T, Tan J, Jemec GBE. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa. Br J Dermatol. 2021 Apr;184(4):681-687. doi: 10.1111/bjd.19344.

HASI-R

Hidradenitis Suppurativa Area and Severity Index, revised

  • Background

    Clinician-reported outcome measures (CROs) that are valid, reliable, feasible and sensitive to change are critical for evaluating response of HS to therapy. While most CRO for HS are based on lesion counts, which can have problematic inter-rater reliability, the HASI-R is based on body surface area assessment, similar to other validated tools such as the PASI and EASI.

    Instrument

    The HASI-R assesses HS activity at ten body sites including: head/neck, left axilla, right axilla, chest, abdomen, back, buttocks including intergluteal cleft, right thigh, left thigh, and pubic area/genitals. Extent of HS is assessed using BSA for each body site. Raters were asked to only score active disease. At each site, the rater also grades the severity of four domains: inflammatory color change, inflammatory induration, open skin surface and extent of tunnels.

    The HASI-R is only available in English.

    Request a License

  • Development

    Development of the HASI-R was based off the concurrent development of the original Hidradenitis Suppurativa Activity and Severity Index (HASI) and the Severity and Area Score for Hidradenitis Suppurativa (SASH). Subsequently, the two groups collaborated to develop the HASI-R through included semi-structured physician interviews, a review of the literature on severity assessment tools, and suggestions from the U.S. Food and Drug Administration (FDA).

    The inter-rater and intra-rater reliability as well as construct and known groups validity were evaluated in a multi-rater study with assessment of multiple patients with HS, that represented a broad range of HS severity and affected body sites. Details of the development of the HASI-R can be found in the References section.

    Training online or in-person is encouraged to ensure valid use in studies.

  • Scoring

    Each item of the HASI-R should be scored by the clinician if it is judged to be due to active HS. Skin findings due to other conditions, including previously active disease, skin damage, infection or comorbidity should not be included in the clinical assessment for the HASI-R.

    Each of the four severity domains is scored on a Likert scale from 0 to 3 (0 = none; 1 = limited/mild, 2 = moderate, 3 = severe/extensive) based on the average intensity across the lesions at each body site. The maximum intensity score for each body site is 12 (maximum score of 3, across 4 components). The BSA score for each HS-specific site is calculated as the proportion of the site involved by HS. This is converted to a 0–6 ordinal scale, (0 points = 0 BSA, 1 point =1–3%, 2 points = 4–9%, 3 points= 10–20%, 4 points= 21–29%, 5 points= 30–50%, 6 points= >51%). To calculate HASI-R, the site-specific score is calculated by multiplying the BSA ordinal score by the sum of the four intensity scores. The maximum score for each body site is 72, thus the score range for the total body HASI-R score is 0 to 720, with higher scores indicating more severe disease activity.

  • References

    Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. Br J Dermatol. 2021 May;184(5):905-912. doi: 10.1111/bjd.19565.

    Goldfarb N, Ingram JR, Jemec GBE, Naik HB, Piguet V, Hyde MJ, Freese R, Lowes MA, Alavi A. Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. Br J Dermatol. 2020 Jan;182(1):240-242. doi: 10.1111/bjd.18335.

    Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. Br J Dermatol. 2020 Apr;182(4):940-948. doi: 10.1111/bjd.18244.

    Bellefeuille G, Paiewonsky B, Khalid B, Freese RL, Lowes MA, Kirby JS, Alavi A, Goldfarb N. Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity. Br J Dermatol. 2023 Aug 24;189(3):338-354. doi: 10.1093/bjd/ljad138.

Background

Clinician-reported outcome measures (CROs) that are valid, reliable, feasible and sensitive to change are critical for evaluating response of HS to therapy. While most CRO for HS are based on lesion counts, which can have problematic inter-rater reliability, the HASI-R is based on body surface area assessment, similar to other validated tools such as the PASI and EASI.

Instrument

The HASI-R assesses HS activity at ten body sites including: head/neck, left axilla, right axilla, chest, abdomen, back, buttocks including intergluteal cleft, right thigh, left thigh, and pubic area/genitals. Extent of HS is assessed using BSA for each body site. Raters were asked to only score active disease. At each site, the rater also grades the severity of four domains: inflammatory color change, inflammatory induration, open skin surface and extent of tunnels.

The HASI-R is only available in English.

Request a License

Development

Development of the HASI-R was based off the concurrent development of the original Hidradenitis Suppurativa Activity and Severity Index (HASI) and the Severity and Area Score for Hidradenitis Suppurativa (SASH). Subsequently, the two groups collaborated to develop the HASI-R through included semi-structured physician interviews, a review of the literature on severity assessment tools, and suggestions from the U.S. Food and Drug Administration (FDA).

The inter-rater and intra-rater reliability as well as construct and known groups validity were evaluated in a multi-rater study with assessment of multiple patients with HS, that represented a broad range of HS severity and affected body sites. Details of the development of the HASI-R can be found in the References section.

Training online or in-person is encouraged to ensure valid use in studies.

Scoring

Each item of the HASI-R should be scored by the clinician if it is judged to be due to active HS. Skin findings due to other conditions, including previously active disease, skin damage, infection or comorbidity should not be included in the clinical assessment for the HASI-R.

Each of the four severity domains is scored on a Likert scale from 0 to 3 (0 = none; 1 = limited/mild, 2 = moderate, 3 = severe/extensive) based on the average intensity across the lesions at each body site. The maximum intensity score for each body site is 12 (maximum score of 3, across 4 components). The BSA score for each HS-specific site is calculated as the proportion of the site involved by HS. This is converted to a 0–6 ordinal scale, (0 points = 0 BSA, 1 point =1–3%, 2 points = 4–9%, 3 points= 10–20%, 4 points= 21–29%, 5 points= 30–50%, 6 points= >51%). To calculate HASI-R, the site-specific score is calculated by multiplying the BSA ordinal score by the sum of the four intensity scores. The maximum score for each body site is 72, thus the score range for the total body HASI-R score is 0 to 720, with higher scores indicating more severe disease activity.

References

Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. Br J Dermatol. 2021 May;184(5):905-912. doi: 10.1111/bjd.19565.

Goldfarb N, Ingram JR, Jemec GBE, Naik HB, Piguet V, Hyde MJ, Freese R, Lowes MA, Alavi A. Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. Br J Dermatol. 2020 Jan;182(1):240-242. doi: 10.1111/bjd.18335.

Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. Br J Dermatol. 2020 Apr;182(4):940-948. doi: 10.1111/bjd.18244.

Bellefeuille G, Paiewonsky B, Khalid B, Freese RL, Lowes MA, Kirby JS, Alavi A, Goldfarb N. Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity. Br J Dermatol. 2023 Aug 24;189(3):338-354. doi: 10.1093/bjd/ljad138.

Contact Us

For additional information, email us at HiSQOL@psu.edu.